New Approaches Logo - Large Oak tree with roots going down into the groundNew Approaches to Cancer through positive self help
Registered Charity 285530          

What's New
About Us
Contact Us
How Can We Help?
Support Groups
More Information
Links to Other Sites
Fund Raising


picture of green phone0800 389 2662 
+44 1483 757 375


picture of letterPO Box 194
KT16 0WJ, U.K.


(please include your name, address and telephone number)


Click Here
to sign up for our email newsletter notifications


Shopping at Amazon?

Use our link and earn money for New Approaches at the same time

Click here to find out more

 Could Omega 3 hold hope for Alzheimer’s sufferers?

 With more than 750,000 people living with dementia in the UK, new research linking Omega 3 with slower cognitive decline in those with mild Alzheimer’s may provide some hope.

The journal Archives of Neurology has published the results of a randomised, double-blind placebo controlled clinical trial suggesting those with very mild Alzheimer’s Disease (AD) – the most common form of dementia - may experience slower mental decline with supplementation of the fatty acids.

The objective of the study was to determine whether dietary Omega 3 supplementation had an effect on patients with mild to moderate Alzheimer’s disease.

A total of 204 patients took part, with some being put into the Omega 3 fatty-acid treated group and others into a placebo group for six months. After the six months, both groups took the fatty acid for a further six months.

In patients with very mild cognitive dysfunction, “a significant reduction in MMSE decline rate was observed in the Omega 3 fatty-acid treated group compared with the placebo group”.

The researchers concluded there was no delay in the rate of cognitive decline in those with mild to moderate AD but said “positive effects were observed in a small group of patients with very mild AD”.

Click here to Link to the Archives of Neurology website



arrow pointing back  <<back to information page    copyright 2017 New Approaches to Cancer.  All rights reserved